arcadia biosciences inc - RKDA

RKDA

Close Chg Chg %
2.26 0.00 0.00%

Pre-Market

2.26

0.00 (0.00%)

Volume: 14.81K

Last Updated:

Jan 22, 2026, 4:00 PM EDT

Company Overview: arcadia biosciences inc - RKDA

RKDA Key Data

Open

$2.32

Day Range

2.24 - 2.34

52 Week Range

1.77 - 6.71

Market Cap

$3.10M

Shares Outstanding

1.37M

Public Float

1.36M

Beta

0.57

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$3.71

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

30.35K

 

RKDA Performance

1 Week
 
-5.83%
 
1 Month
 
-13.08%
 
3 Months
 
-44.88%
 
1 Year
 
-55.86%
 
5 Years
 
-98.36%
 

RKDA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About arcadia biosciences inc - RKDA

Arcadia Biosciences, Inc. is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include Zola coconut water and agronomic wheat traits. It operates through the following geographical segments: United States, Argentina, India, and Canada. The company was founded by John G. Sperling in 2002 and is headquartered in Dallas, TX.

RKDA At a Glance

Arcadia Biosciences, Inc.
5950 Sherry Lane
Dallas, Texas 75225
Phone 1-214-974-8921 Revenue 5.05M
Industry Chemicals: Agricultural Net Income -7,038,000.00
Sector Process Industries Employees 9
Fiscal Year-end 12 / 2025
View SEC Filings

RKDA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.60
Price to Book Ratio 1.298
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.822
Enterprise Value to Sales 0.79
Total Debt to Enterprise Value 0.039

RKDA Efficiency

Revenue/Employee 560,555.556
Income Per Employee -782,000.00
Receivables Turnover 1.644
Total Asset Turnover 0.304

RKDA Liquidity

Current Ratio 3.606
Quick Ratio 3.253
Cash Ratio 1.655

RKDA Profitability

Gross Margin 41.269
Operating Margin -111.239
Pretax Margin -85.411
Net Margin -139.504
Return on Assets -25.989
Return on Equity -45.29
Return on Total Capital -67.686
Return on Invested Capital -44.924

RKDA Capital Structure

Total Debt to Total Equity 2.491
Total Debt to Total Capital 2.43
Total Debt to Total Assets 1.147
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Arcadia Biosciences Inc - RKDA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
6.78M 9.96M 5.33M 5.04M
Sales Growth
-15.61% +46.84% -46.46% -5.35%
Cost of Goods Sold (COGS) incl D&A
8.71M 9.80M 3.30M 2.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.04M 1.36M 984.00K 765.00K
Depreciation
929.00K 1.32M 984.00K 765.00K
Amortization of Intangibles
- - 116.00K 40.00K
-
COGS Growth
+67.49% +12.56% -66.33% -10.21%
Gross Income
(1.93M) 154.00K 2.03M 2.08M
Gross Income Growth
-168.01% +107.99% +1,218.18% +2.56%
Gross Profit Margin
-28.44% +1.55% +38.09% +41.27%
2021 2022 2023 2024 5-year trend
SG&A Expense
25.98M 19.56M 15.89M 7.69M
Research & Development
3.89M 1.51M 1.39M 53.00K
Other SG&A
22.09M 18.05M 14.51M 7.64M
SGA Growth
+6.64% -24.71% -18.72% -51.59%
Other Operating Expense
- - - -
-
Unusual Expense
(2.94M) (2.35M) (355.00K) 3.51M
EBIT after Unusual Expense
(24.96M) (17.06M) (13.51M) (9.12M)
Non Operating Income/Expense
8.85M 1.46M 353.00K 4.81M
Non-Operating Interest Income
- 289.00K 695.00K 782.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 20.00K
-
Interest Expense Growth
- - -57.45% -100.00%
-
Gross Interest Expense
- - - 20.00K
-
Interest Capitalized
- - - -
-
Pretax Income
(16.13M) (15.60M) (13.16M) (4.31M)
Pretax Income Growth
-162.31% +3.31% +15.65% +67.25%
Pretax Margin
-237.94% -156.67% -246.85% -85.41%
Income Tax
2.00K 14.00K 8.00K 8.00K
Income Tax - Current - Domestic
2.00K 13.00K 7.00K 8.00K
Income Tax - Current - Foreign
- - 1.00K 1.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(16.13M) (15.61M) (13.16M) (4.32M)
Minority Interest Expense
- (1.47M) (236.00K) (5.00K)
Net Income
(14.66M) (15.38M) (13.16M) (4.32M)
Net Income Growth
-214.93% -4.88% +14.41% +67.20%
Net Margin Growth
-216.22% -154.44% -246.90% -85.57%
Extraordinaries & Discontinued Operations
- - (821.00K) (2.72M)
-
Discontinued Operations
- - (821.00K) (2.72M)
-
Net Income After Extraordinaries
(14.66M) (15.38M) (13.98M) (7.04M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(14.66M) (15.38M) (13.98M) (7.04M)
EPS (Basic)
-27.5556 -25.6528 -11.3029 -5.1625
EPS (Basic) Growth
-47.38% +6.91% +55.94% +54.33%
Basic Shares Outstanding
532.02K 599.39K 1.24M 1.36M
EPS (Diluted)
-27.5556 -25.6528 -11.3029 -5.1625
EPS (Diluted) Growth
-47.38% +6.91% +55.94% +54.33%
Diluted Shares Outstanding
532.02K 599.39K 1.24M 1.36M
EBITDA
(26.86M) (18.04M) (12.88M) (4.85M)
EBITDA Growth
-28.74% +32.84% +28.60% +62.37%
EBITDA Margin
-396.17% -181.20% -241.67% -96.08%

Snapshot

Average Recommendation BUY Average Target Price 12.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.848 Median PE on CY Estimate N/A
Year Ago Earnings -3.17 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Arcadia Biosciences Inc in the News